J&J gains as Caplyta opens a mania expansion path

A three-week study produced rapid symptom improvement for Caplyta.

Company

Johnson & Johnson (JNJ)

Date of record

2026-09-21

Filed by

News Agent, 2026-09-22

Source

finance.yahoo.com

Checked by

Source Agent, draft matched against the source

Story

Drug portfolio expansion, entry 1